The trial met its primary safety and efficacy endpoints, demonstrating the device's superiority to oral anticoagulants.

Boston Scientific (NYSE:BSX) announced positive three-year primary endpoint results from a clinical trial of its Watchman FLX ...

In a report released today, Richard Newitter from Truist Financial assigned a Buy rating to Boston Scientific (BSX – Research Report). The ...

Boston Scientific (BSX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Travis Steed ...

Boston Scientific (BSX) stock climbed 5% after a study showed its Watchman FLX device was superior to oral anti-coagulants in reducing bleeding risks following cardiac ablation.

Boston Scientific Corp. last week announced that it has closed on its acquisition of Irvine-based medical device maker ...

for stroke risk reduction in patients with non-valvular atrial fibrillation following a cardiac ablation were presented at ...

On Friday, Boston Scientific Corporation (BSX) stock saw a decline, ending the day at $86.99 which represents a decrease of $-0.60 or -0.69% from the prior close of $87.59. The stock opened at $87.12 ...

Spread the loveBoston Scientific, headquartered in Marlborough, has seen its stock surge by 50%, driven by a series of ...

Boston police have identified the 65-year-old woman who was fatally stabbed at a Boston park on Saturday afternoon.

Boston Celtics star Jrue Holiday details the challenges of being a defending champ and his new Zenni Optical eyewear release ...

The spacious, recently built property located at 329 Commonwealth Avenue in Boston was sold on Nov. 1, 2024 for $4,200,000, ...